Research Papers:

Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer

Olga A. Timofeeva, Nancy Palechor-Ceron, Guanglei Li, Hang Yuan, Ewa Krawczyk, Xiaogang Zhong, Geng Liu, Geeta Upadhyay, Aleksandra Dakic, Songtao Yu, Shuang Fang, Sujata Choudhury, Xueping Zhang, Andrew Ju, Myeong-Seon Lee, Han C. Dan, Youngmi Ji, Yong Hou, Yun-Ling Zheng, Chris Albanese, Johng Rhim, Richard Schlegel, Anatoly Dritschilo and Xuefeng Liu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:22741-22758. https://doi.org/10.18632/oncotarget.13937

Metrics: PDF 4370 views  |   HTML 6824 views  |   ?  


Olga A. Timofeeva1,2, Nancy Palechor-Ceron3, Guanglei Li4, Hang Yuan3, Ewa Krawczyk3, Xiaogang Zhong5, Geng Liu4, Geeta Upadhyay1, Aleksandra Dakic3, Songtao Yu3, Shuang Fang3, Sujata Choudhury3, Xueping Zhang1, Andrew Ju6, Myeong-Seon Lee7, Han C. Dan8, Youngmi Ji9, Yong Hou4, Yun-Ling Zheng1, Chris Albanese1,3, Johng Rhim9, Richard Schlegel3, Anatoly Dritschilo1,6, Xuefeng Liu3

1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA

2Department of Pathology and Laboratory Medicine, Lewis Katz Medical School, Temple University, Philadelphia, PA, USA

3Department of Pathology and Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC, USA

4Beijing Genome Research Institute, Shenzhen, Guangdong, China

5Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA

6Department of Radiation Medicine, Georgetown University Medical School, Washington, DC, USA

7Department of Biomedical Science, Cheongju University, Sandang-Gu, Cheongju Shi Chungbuk, Republic of Korea

8Department of Pathology, University of Maryland, Baltimore, MD, USA

9Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

Correspondence to:

Xuefeng Liu, email: [email protected]

Anatoly Dritschilo, email: [email protected]

Olga A. Timofeeva, email: [email protected]

Keywords: prostate cancer, conditional cell reprogramming, cell lines, patient-derived, cancer cell models

Received: June 13, 2016    Accepted: November 22, 2016    Published: December 21, 2016


Our previous study demonstrated that conditional reprogramming (CR) allows the establishment of patient-derived normal and tumor epithelial cell cultures from a variety of tissue types including breast, lung, colon and prostate. Using CR, we have established matched normal and tumor cultures, GUMC-29 and GUMC-30 respectively, from a patient’s prostatectomy specimen. These CR cells proliferate indefinitely in vitro and retain stable karyotypes. Most importantly, only tumor-derived CR cells (GUMC-30) produced tumors in xenografted SCID mice, demonstrating maintenance of the critical tumor phenotype. Characterization of cells with DNA fingerprinting demonstrated identical patterns in normal and tumor CR cells as well as in xenografted tumors. By flow cytometry, both normal and tumor CR cells expressed basal, luminal, and stem cell markers, with the majority of the normal and tumor CR cells expressing prostate basal cell markers, CD44 and Trop2, as well as luminal marker, CD13, suggesting a transit-amplifying phenotype. Consistent with this phenotype, real time RT-PCR analyses demonstrated that CR cells predominantly expressed high levels of basal cell markers (KRT5, KRT14 and p63), and low levels of luminal markers. When the CR tumor cells were injected into SCID mice, the expression of luminal markers (AR, NKX3.1) increased significantly, while basal cell markers dramatically decreased. These data suggest that CR cells maintain high levels of proliferation and low levels of differentiation in the presence of feeder cells and ROCK inhibitor, but undergo differentiation once injected into SCID mice. Genomic analyses, including SNP and INDEL, identified genes mutated in tumor cells, including components of apoptosis, cell attachment, and hypoxia pathways. The use of matched patient-derived cells provides a unique in vitro model for studies of early prostate cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13937